Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Thomas N O'Connor; Emily Schultz; Sheheryar Kabraji; EG Levine; Amy J Williams; Erik S Knudsen; Agnieszka K. Witkiewicz

doi:10.1200/po-25-00346

January 1, 2026

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the role of plasma thymidine kinase activity as a prognostic and predictive biomarker in breast cancer treatment.
Assessed circulating thymidine kinase levels in patients with high-risk metastatic breast cancer.
Analyzed the relationship between thymidine kinase levels and response to CDK4/6 inhibitor therapy.
Planned future studies to determine specific cutoff values for treatment decisions.
Findings indicate that higher thymidine kinase activity may correlate with better treatment response.
The study suggests circulating thymidine kinase could serve as a continuous biomarker.
Future investigations are necessary to establish definitive cutoff levels for clinical use.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational study investigates thymidine kinase levels as a biomarker in breast cancer, suggesting future treatment applications.

Abstract

These findings support further investigation of circulating TKa levels as a continuous prognostic and predictive biomarker of response to CDK4/6 inhibitor-based therapy. Future studies are well-suited to assess definitive TKa cutoff values to inform treatment decisions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

O'Connor et al. (2026) studied this question.

synapsesocial.com/papers/69770370722626c4468e86e4 https://doi.org/10.1200/po-25-00346

View at Publisher

Ask AI

Bookmark

Share

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading